RxDoctor Payments Data

Alexandra Coromilas, MD

Dermatology · New York, NYNPI 1871972703

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 31.1% of the total. Reporting peaked in 2023 at $241 and has fallen 83.3% since, to $40 in 2025. That places this record below the midpoint for dermatology clinicians in NY, where the typical reported total is $2,360.

$689in general payments, 2019–2025

Across 15 payments — averaging $45.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$214
  • Galderma Laboratories, L.p.$172
  • Abbott$137
  • Incyte Corporation$40
  • Pfizer$39
  • UCB, Inc.$30
  • plus $56 from 2 others

What the payments were for

  • Food & beverage$66597%
  • Education$243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$689 in reported general payments places this provider in the 30th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York →

Medicare billing

Part B allowed, 2024
$152,897
Medicare patients
573
Services billed
1,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab19$282,969
Dupixent SyringeDupilumab28$99,673
Taltz AutoinjectorIxekizumab11$76,462
Dupixent PenDupilumab13$47,099
Tacrolimus113$13,860
Acitretin41$8,382
Ketoconazole279$5,763
Clobetasol Propionate129$5,300
Calcipotriene40$4,601
Pimecrolimus27$3,140
Triamcinolone Acetonide247$3,056
Fluocinonide59$2,652
Clindamycin Phosphate69$2,409
Fluorouracil42$2,111
Tretinoin31$2,024

Paid to pharmacies, not to this prescriber.

Other dermatology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →